Status:
UNKNOWN
Comparison of the Human Papillomavirus (HPV) Type 16 E7-Specific Immune Response Between a Normal Population and Patients With Cervical Lesions
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Cervical Cancer
Eligibility:
FEMALE
18-80 years
Brief Summary
Cervical cancer is the most frequent neoplasm and the third in mortality rate of the malignancies in women in the world. It results in about 200,000 women dying of cervical cancer each year worldwide....
Detailed Description
HPV and Cervical Cancers: Human papillomaviruses (HPV) are small, nonenveloped DNA viruses which induce epithelial tumors of skin or mucosa. The majority of tumors are benign, show limited growth and...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Healthy volunteers
- People infected with HPV type 16 but without CIN lesions
- Patients with CIN lesions
- Patients with cervical cancer from National Taiwan University Hospital
- Informed consent is obtained, and the protocols are reviewed and approved by the appropriate Investigative Review Boards.
Exclusion
Key Trial Info
Start Date :
January 1 2003
Trial Type :
OBSERVATIONAL
End Date :
December 1 2008
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00154583
Start Date
January 1 2003
End Date
December 1 2008
Last Update
December 21 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan